Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $26,399.86 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 1,334 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $19.79, for a total value of $26,399.86. Following the sale, the insider directly owned 81,724 shares in the company, valued at $1,617,317.96. This trade represents a 1.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Mark Jeffrey Delong also recently made the following trade(s):

• On Tuesday, January 13th, Mark Jeffrey Delong sold 1,780 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total value of $39,498.20.

Apellis Pharmaceuticals Price Performance

APLS traded up $0.48 during trading on Wednesday, reaching $20.95. 3,751,970 shares of the company traded hands, compared to its average volume of 3,365,575. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $31.17. The firm has a fifty day simple moving average of $22.93 and a 200 day simple moving average of $23.52. The company has a market cap of $2.65 billion, a P/E ratio of 67.58 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The firm had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. The company’s quarterly revenue was up 133.0% compared to the same quarter last year. On average, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Stifel Nicolaus reduced their target price on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Mizuho cut their price target on Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating for the company in a report on Monday, November 3rd. JPMorgan Chase & Co. reduced their price objective on Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Bank of America upgraded Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Wednesday. Finally, HC Wainwright reduced their price target on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Twelve investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $33.53.

Apellis Pharmaceuticals News Summary

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded Apellis from neutral to buy and set a $28 price target, citing strong early launch trajectory for the company’s kidney-disease therapy — a clear near-term catalyst for revenue upside. Apellis upgraded at BofA on launch trajectory for kidney disease therapy
• Positive Sentiment: An analyst note in Benzinga highlights that current valuation may underappreciate Empaveli (the company’s therapy) potential and early uptake in a rare kidney-disease market, signaling a possible multi-year revenue inflection if adoption continues. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target from $29 to $26 but kept an overweight rating, reflecting a modest reset to near-term expectations while still projecting upside versus current levels. Wells Fargo trims price target to $26
• Neutral Sentiment: RBC Capital reiterated a hold rating for Apellis, indicating some analysts remain cautious despite positive launch signals. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Two insiders sold shares on Jan. 20 — CFO Timothy Sullivan sold 2,892 shares and General Counsel David Watson sold 2,475 shares. While both still hold large positions, insider sales can be perceived negatively by investors monitoring insider conviction. Form 4 – Timothy Eugene Sullivan Form 4 – David O. Watson

Institutional Investors Weigh In On Apellis Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Marshall Wace LLP increased its position in shares of Apellis Pharmaceuticals by 11,373.8% during the 2nd quarter. Marshall Wace LLP now owns 2,704,837 shares of the company’s stock valued at $46,821,000 after purchasing an additional 2,681,263 shares during the last quarter. Norges Bank purchased a new position in Apellis Pharmaceuticals during the second quarter worth $40,977,000. AQR Capital Management LLC increased its position in Apellis Pharmaceuticals by 46.6% during the second quarter. AQR Capital Management LLC now owns 5,976,414 shares of the company’s stock valued at $103,452,000 after acquiring an additional 1,898,995 shares during the last quarter. Polar Capital Holdings Plc raised its stake in shares of Apellis Pharmaceuticals by 96.0% in the third quarter. Polar Capital Holdings Plc now owns 2,650,230 shares of the company’s stock valued at $59,975,000 after acquiring an additional 1,298,055 shares during the period. Finally, Amundi raised its stake in shares of Apellis Pharmaceuticals by 386.7% in the second quarter. Amundi now owns 1,604,105 shares of the company’s stock valued at $28,585,000 after acquiring an additional 1,274,523 shares during the period. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.